This reports provides a data-driven overview of the current and future competitive landscape in BDC therapeutics.
Synopsis
- In 2022, there will be more than 71,000 diagnosed prevalent cases of bile duct cancer across 16 pharmaceutical markets
- There are seven marketed innovator drugs for the treatment of bile duct cancer, mostly tyrosine kinase inhibitors
- R&D activity in bile duct cancer is robust globally, with three products in pre-registration and 16 products in Phase III development in the US, EU, Asia, and global markets
- Institutional sponsors dominated the clinical trial development in bile duct cancer, with UK emerging as the key country for conducting Phase III trials in bile duct cancer
- During the past 12 months, six strategic alliances and one merger and acquisition transactions involving bile duct cancer assets were successfully completed
- Approvals expected in near future for molecules from key companies such as AstraZeneca, Otsuka and Servier
Scope
The publisher's Bile Duct Cancer (Cholangiocarcinoma) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.Components of the report include:
- Disease Landscape
- Disease Overview
- Epidemiology Overview
- Treatment Overview
- Marketed Products Assessment
- Breakdown by Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Pricing and Reimbursement Assessment
- Retail or Manufacturer Price of Products
- Time to Pricing and Time to Reimbursement
- Pipeline Assessment
- Breakdown by Development Stage, Mechanism of Action, Molecule Type, Route of Administration
- Product Profiles with Sales Forecast
- Late-to-mid-stage Pipeline Drugs
- Phase Transition Success Rate and Likelihood of Approval
- Clinical Trials Assessment
- Breakdown of Trials by Phase, Status, Virtual Components, Sponsors, Geography, and Endpoint Status
- Enrolment Analytics, Site Analytics, Feasibility Analysis
- Deals Landscape
- Mergers, Acquisitions, and Strategic Alliances by Region
- Overview of Recent Deals
- Commercial Assessment
- Key Market Players
- Future Market Catalysts
Reasons to Buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline
- Develop business strategies by understanding the trends shaping and driving the BDC market
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global BDC market in the future
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
Table of Contents
1 Preface
3 Disease Landscape
4 Marketed Drugs Assessment
5 Pricing and Reimbursement Assessment
6 Pipeline Drugs Assessment
7 Clinical Trials Assessment
8 Deals Landscape
9 Commercial Assessment
11 Appendix
